These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34 related articles for article (PubMed ID: 22260350)
1. Immunostaining for mismatch repair (MMR) protein expression in colorectal cancer is better and easier to interpret when performed on diagnostic biopsies. Fadhil W; Ilyas M Histopathology; 2012 Mar; 60(4):653-5. PubMed ID: 22260350 [No Abstract] [Full Text] [Related]
2. DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material. Kumarasinghe AP; de Boer B; Bateman AC; Kumarasinghe MP Pathology; 2010; 42(5):414-20. PubMed ID: 20632816 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Bao F; Panarelli NC; Rennert H; Sherr DL; Yantiss RK Am J Surg Pathol; 2010 Dec; 34(12):1798-804. PubMed ID: 21107085 [TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status. Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486 [TBL] [Abstract][Full Text] [Related]
5. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Losi L; Di Gregorio C; Pedroni M; Ponti G; Roncucci L; Scarselli A; Genuardi M; Baglioni S; Marino M; Rossi G; Benatti P; Maffei S; Menigatti M; Roncari B; Ponz de Leon M Am J Gastroenterol; 2005 Oct; 100(10):2280-7. PubMed ID: 16181381 [TBL] [Abstract][Full Text] [Related]
6. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Aaltonen L; Johns L; Järvinen H; Mecklin JP; Houlston R Clin Cancer Res; 2007 Jan; 13(1):356-61. PubMed ID: 17200375 [TBL] [Abstract][Full Text] [Related]
7. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. Jensen LH; Lindebjerg J; Byriel L; Kolvraa S; Crüger DG Colorectal Dis; 2008 Jun; 10(5):490-7. PubMed ID: 17868408 [TBL] [Abstract][Full Text] [Related]
8. [Mismatch repair (MMR) efficiency and MSH2 gene mutation in human colorectal carcinoma cell line COLO320HSR]. Tronov VA; Kramarenko II; Maĭorova EN; Zakharov SF Genetika; 2007 Apr; 43(4):537-44. PubMed ID: 17555131 [TBL] [Abstract][Full Text] [Related]
9. HMSH6 alterations in patients with microsatellite instability-low colorectal cancer. Parc YR; Halling KC; Wang L; Christensen ER; Cunningham JM; French AJ; Burgart LJ; Price-Troska TL; Roche PC; Thibodeau SN Cancer Res; 2000 Apr; 60(8):2225-31. PubMed ID: 10786688 [TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706 [TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. Sánchez-de-Abajo A; de la Hoya M; van Puijenbroek M; Tosar A; López-Asenjo JA; Díaz-Rubio E; Morreau H; Caldes T Clin Cancer Res; 2007 Oct; 13(19):5729-35. PubMed ID: 17908962 [TBL] [Abstract][Full Text] [Related]
17. The Importance of Immunohistochemical Heterogeneous Expression of MMR Protein in Patients with Colorectal Cancer in Stage II and III of the Disease. Denčić T; Petrović A; Jovičić Milentijević M; Radenković G; Jović M; Živković N; Šalinger S; Branković B; Veličkov A; Ilić I Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984490 [No Abstract] [Full Text] [Related]
19. Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis. Aiyer KTS; Doeleman T; Ryan NA; Nielsen M; Crosbie EJ; Smit VTHBM; Morreau H; Goeman JJ; Bosse T Mod Pathol; 2022 Dec; 35(12):1775-1783. PubMed ID: 36104536 [TBL] [Abstract][Full Text] [Related]
20. Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. Kullmann F; Strissel PL; Strick R; Stoehr R; Eckstein M; Bertz S; Wullich B; Sikic D; Wach S; Taubert H; Olbert P; Heers H; Lara MF; Macias ML; Matas-Rico E; Lozano MJ; Prieto D; Hierro I; van Doeveren T; Bieche I; Masliah-Planchon J; Beaurepere R; Boormans JL; Allory Y; Herrera-Imbroda B; Hartmann A; Weyerer V J Clin Pathol; 2023 Feb; 76(2):126-132. PubMed ID: 34583948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]